Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 13;9(2):553.
doi: 10.37029/jcas.v9i2.553. eCollection 2023.

Outcomes of Patients with FLT3 Positive Acute Myeloid Leukaemia; an Experience from a Tertiary Care Hospital in Karachi, Pakistan

Maria Zulfiqar  1 , Natasha Ali  2 , Usman Shaikh  2 , Hamzah Jehanzeb  3 , Salman Arif  1 , Zurrya Fasih Khan  1 , Nabiha Saeed  1 , Zeeshan Ansar  4
Affiliations

Outcomes of Patients with FLT3 Positive Acute Myeloid Leukaemia; an Experience from a Tertiary Care Hospital in Karachi, Pakistan

Maria Zulfiqar et al. J Cancer Allied Spec. .

Abstract

Introduction: Molecular genetic abnormalities in acute myeloid leukaemia (AML) are essential for disease diagnosis and determining prognosis and clinical course. Mutations in FLT3 and nucleophosmin (NPM) genes are the most frequent genetic abnormalities, which are also known to impact disease outcomes. FLT3 mutations have been identified in approximately 30% of de novo AML patients and are associated with poor prognoses. This study aimed to determine the response to induction chemotherapy, overall survival (OS) and relapse rate (RR) in patients with FLT3-positive AML.

Materials and methods: In this study, a retrospective analysis was performed of 75 newly diagnosed patients with AML registered between January 2015 and July 2022. Patient demographics and clinical-haematological parameters were noted and molecular analysis for FLT3 ITD/TKD and NPM mutations was performed. All the patients received standard induction chemotherapy and their response to treatment, OS and RR were assessed.

Results: A total of 75 cases of AML were analysed. The mean age of the sample was 34.9 years, of which 65.3% were males and 34.7% were females. The patients were stratified into two groups: Those who were positive for FLT3 while negative for NPM (FLT3+/NPM-), representing 17.3% and those who were negative for both FLT3 and NPM (FLT3-/NPM-), representing 82.7% of cases. On day 28 post-induction, the complete remission rate was 69.2% in the FLT3 positive group and 77.4% in the FLT3 negative group. In the FLT3+/NPM- group, 55.6% of cases who were in remission at day 28 subsequently relapsed, compared to 50.0% of FLT3-/NPM- cases. The overall median survival time for the cohort and FLT3+ group was 1467 days, while that of the FLT3-group could not be estimated due to the very high survival rate.

Conclusion: No significant differences in outcomes were observed in patients who were FLT3 positive compared to those who were FLT3 negative.

Keywords: Acute myeloid leukaemia; Complete remission; FLT-3 ITD; FLT-3TKD; NPM-1; Overall survival Relapse rate.

PubMed Disclaimer

Conflict of interest statement

The author(s) declare(s) that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve for survival
Figure 2
Figure 2
Kaplan–Meier curve for remission
See this image and copyright information in PMC

References

    1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–42. - PubMed
    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours:Myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. - PMC - PubMed
    1. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy:Analysis of 854 patients from the United Kingdom medical research council AML 10 and 12 trials. Blood. 2001;98:1752–9. - PubMed
    1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML:Review of current knowledge and evidence. Leukemia. 2019;33:299–312. - PMC - PubMed
    1. Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, et al. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS One. 2014;9:e89560. - PMC - PubMed

LinkOut - more resources